Science Board Investigates How FDA Has Responded To Critical 2007 Report
This article was originally published in The Gray Sheet
Executive Summary
A subcommittee is evaluating progress the agency has made in regulatory science since the 2007 report, “FDA Science and Mission at Risk,” was issued, while identifying future needs.
You may also be interested in...
Device Center Moves To Better Prioritize Its Scientific Work
CDRH Director Jeffrey Shuren says the center is taking multiple steps, including the creation of a new internal subcommittee and possible restructuring to its research offices, in response to critiques from the FDA Science Board on how well CDRH is accomplishing its scientific mission.
Regulatory Briefs: HHS Agenda; Cardiopulmonary Blood Pump Reclassification; FDA Meetings
HHS issued a semiannual report detailing the regulatory agenda for FDA in 2014. FDA reclassifies cardiopulmonary bypass blood pumps. More regulatory news.
CDRH Scientists Need To Focus On Regulatory Mission, Advertise Successes – Science Board Report
Investment in CDRH regulatory science is “non-negotiable,” but the center’s efforts need to be appropriately focused, and it should do a better job of measuring and communicating success, an FDA Science Advisory Board Subcommittee report finds.